EVIDENCE MAP OF INDIRECT COSTS IN PSORIASIS AND PSORIATIC ARTHRITIS SINCE 1960
Author(s)
Martin A
Crystallise Ltd., East Tilbury, UK
Presentation Documents
OBJECTIVES: To create an evidence map of studies reporting the indirect costs associated with psoriasis and psoriatic arthritis, and the geographical settings in which these studies were conducted.
METHODS: We searched the heoro.com database (www.heoro.com) for abstracts reporting indirect costs in psoriasis or psoriatic arthritis published between 1960 and 1st June 2017, interventions and study methodologies
RESULTS: We found a total of Twenty nine abstracts reported on observational cost of illness studies or those with patient-reported productivity assessments, nine included indirect costs in an economic model, seven assessed indirect costs as part of a clinical trial and 12 were reviews of the literature. Interventions studied included targeted therapies, in particular adalimumab (8 abstracts), etanercept (8), ustekinumab (5)and infliximab (3), phototherapy (6), corticosteroids (4) and cyclosporine (2), although no specific treatment was cited in 28 abstracts. Two papers were published before 2000, 16 between 2000 and 2009, and 39 between 2010 and 2017.CONCLUSIONS: As with many diseases, there is a relative lack of published data on indirect costs of psoriasis and psoriatic arthritis, and of studies reporting indirect cost data were from four jurisdictions: the US, Germany, the UK and Italy
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PSS23
Topic
Economic Evaluation
Topic Subcategory
Work & Home Productivity - Indirect Costs
Disease
Sensory System Disorders